Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Esophageal Perforation-II: Clinical Manifestations and Management01:28

Esophageal Perforation-II: Clinical Manifestations and Management

702
Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
702
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

1.0K
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
1.0K
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.2K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.2K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

557
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
557
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

817
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
817
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

225
Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
225

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Identifying distinct clinical phenotypes and outcomes in adult-onset IgA vasculitis using unsupervised clustering analysis" [European Journal of Internal Medicine 147 (2026) 106742].

European journal of internal medicine·2026
Same author

French recommendations for the use of imaging in giant cell arteritis.

Joint bone spine·2026
Same author

Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review.

BMJ open·2026
Same author

Complete PET/CT extinction and subsequent risk of aortic dilation in patients with giant cell arteritis-related large vessel vasculitis treated with tocilizumab.

RMD open·2026
Same author

Stroke characteristics in giant cell arteritis and Takayasu arteritis: A multicenter retrospective cohort study of 108 patients.

Seminars in arthritis and rheumatism·2026
Same author

Identifying distinct clinical phenotypes and outcomes in adult-onset IgA vasculitis using unsupervised clustering analysis.

European journal of internal medicine·2026

Related Experiment Video

Updated: Jan 26, 2026

Recording Horizontal Saccade Performances Accurately in Neurological Patients Using Electro-oculogram
06:12

Recording Horizontal Saccade Performances Accurately in Neurological Patients Using Electro-oculogram

Published on: March 13, 2018

11.1K

Polyarteritis Nodosa Neurologic Manifestations.

Hubert de Boysson1, Loïc Guillevin2

  • 1Department of Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France.

Neurologic Clinics
|April 7, 2019
PubMed
Summary

Polyarteritis nodosa (PAN) is a vasculitis impacting medium vessels, causing diverse symptoms like neuropathy and organ damage. Treatment involves corticosteroids, immunosuppressants, and antivirals for specific cases.

Keywords:
ANCAHepatitis B virusPeripheral neuropathyPolyarteritis nodosaStrokeVasculitis

More Related Videos

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.5K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.9K

Related Experiment Videos

Last Updated: Jan 26, 2026

Recording Horizontal Saccade Performances Accurately in Neurological Patients Using Electro-oculogram
06:12

Recording Horizontal Saccade Performances Accurately in Neurological Patients Using Electro-oculogram

Published on: March 13, 2018

11.1K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.5K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.9K

Area of Science:

  • Rheumatology
  • Immunology
  • Neurology

Background:

  • Polyarteritis nodosa (PAN) is a critical necrotizing vasculitis targeting medium-sized arteries.
  • Key clinical features include weight loss, fever, neuropathy, and potential organ damage (renal, GI, cutaneous).
  • Peripheral neuropathy is a common early sign, while central nervous system involvement is rare and typically late-onset.

Purpose of the Study:

  • To summarize the key characteristics and management strategies for Polyarteritis Nodosa.
  • To highlight the prevalence and significance of peripheral neuropathy in PAN patients.
  • To outline treatment protocols based on disease severity and etiology.

Main Methods:

  • Literature review of Polyarteritis Nodosa (PAN) manifestations and treatment.
  • Analysis of symptom frequency, particularly peripheral neuropathy and CNS involvement.
  • Summary of current therapeutic approaches, including immunosuppression and antiviral therapy.

Main Results:

  • PAN presents with systemic symptoms, frequently involving peripheral neuropathy (50-75%) and less commonly CNS (2-10%).
  • Treatment for severe PAN combines corticosteroids with immunosuppressants like cyclophosphamide.
  • Hepatitis B virus-associated PAN requires additional plasma exchange and antiviral therapy.

Conclusions:

  • Early recognition of symptoms like peripheral neuropathy is crucial for PAN diagnosis.
  • Treatment strategies must be tailored to disease severity and specific causes, such as HBV infection.
  • Multidisciplinary management is essential for improving outcomes in Polyarteritis Nodosa patients.